Corvus Pharmaceuticals NASDAQ: CRVS
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Name | Corvus Pharmaceuticals |
Ticker | CRVS |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price
52W Low/High |
2.83
2.15 / 5.37 |
Momentum | Sharp Down |
Market cap | 79 M |
1Y Total Return |
21.46%
Below Average |
1Y Volatility |
101.35%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies
Details
Ticker | CRVS |
Name | Corvus Pharmaceuticals |
ISIN | US2210151005 |
CUSIP | |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/14/21
Close Price | 2.83 |
52W Low/High | 2.15 / 5.37 |
Market cap | 79 M |
1Y Total Return |
21.46%
Below Average |
1Y Volatility |
101.35%
High Risk |
Beta | 2.29 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | - |
Cash from Op. / Cur. Liabilities | -2.86 |
Diluted Earnings / Share | -0.20 |
ROE | - |
ROIC | -9.6% |
Price / Revenue | - |
Price / Book | 1.2 |
Price / CF | -2.4 |
Current Ratio | 3.7 |
Cur.Liabilities / Tot.Liabilities | 0.9 |
Financial Leverage | 0.03 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
|
Gross Profit |
-
|
-
|
-
|
-
|
-
|
-
|
|
R&D |
32
|
38
|
39
|
46
|
29
|
11
|
|
EBITDA |
-5
|
-46
|
-46
|
-55
|
-36
|
-31
|
|
Operating Income |
-44
|
-49
|
-49
|
-57
|
-37
|
-14
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
29
|
29
|
28
|
20
|
15
|
0
|
|
EPS exc. Extra |
-0.20
|
-1.59
|
-1.71
|
-2.72
|
-2.36
|
-83.86
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
86
|
84
|
118
|
95
|
140
|
98
|
|
Cash, Eq & Invt ShortTerm |
44
|
78
|
115
|
90
|
135
|
94
|
|
Total Current Assets |
45
|
79
|
116
|
91
|
136
|
96
|
|
Total Non-Current Assets |
40
|
4
|
3
|
4
|
4
|
3
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
13
|
13
|
8
|
10
|
7
|
4
|
|
Total Current Liabilities |
12
|
10
|
7
|
9
|
6
|
3
|
|
Long Term Debt |
1
|
2
|
1
|
1
|
1
|
1
|
|
Shareholder equity |
72
|
71
|
110
|
85
|
133
|
-31
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-35
|
-37
|
-41
|
-46
|
-28
|
-11
|
|
Depreciation |
1
|
1
|
1
|
1
|
1
|
0
|
|
Cash from Investing |
45
|
3
|
-30
|
85
|
-43
|
-92
|
|
Capex |
0
|
0
|
0
|
0
|
2
|
2
|
|
Cash from Financing |
1
|
0
|
65
|
1
|
71
|
95
|
|
Stock Issued |
1
|
0
|
65
|
1
|
71
|
0
|
|
Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
Free Cash Flow |
42
|
-40
|
-79
|
33
|
-75
|
-123
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
3.7
|
7.8
|
16.4
|
10.2
|
22.9
|
31.2
|
|
Financial Leverage D/E |
0.03
|
0.04
|
0.00
|
0.00
|
0.00
|
-
|
|
Return on Capital Avg |
-9.6%
|
-66.5%
|
-83.3%
|
-65.5%
|
-33.0%
|
-70.7%
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available